Understanding how neuropeptides affect brain signaling in Alzheimer's disease.
Peptidergic Modulation of NMDA-Receptor Mediated Neurotransmission
This study is looking at how certain brain chemicals affect the way nerve cells communicate, which is important for learning and memory, using tiny worms as a model, and the goal is to find new ways to help treat diseases like Alzheimer's.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11092816 on NIH RePORTER |
What this research studies
This research investigates the role of neuropeptides in regulating synaptic function, particularly focusing on NMDA receptors, which are crucial for information processing in the brain. Using the model organism C. elegans, researchers will explore how these peptides influence synaptic signaling and contribute to learning and memory. The study employs advanced techniques such as in vivo electrophysiology, behavioral analysis, and optogenetics to uncover the mechanisms behind these processes. The findings aim to provide insights that could lead to new drug targets for treating neurodegenerative disorders like Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related neurodegenerative conditions.
Not a fit: Patients with non-neurological conditions or those not affected by cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapeutic strategies for Alzheimer's disease and other neurological disorders.
How similar studies have performed: Previous research has shown promising results in understanding synaptic function and neuropeptide signaling, indicating potential for success in this area.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Maricq, Andres Villu — University of Utah
- Study coordinator: Maricq, Andres Villu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.